Standard BioTools Inc. Debt Instrument, Face Amount
Standard BioTools Inc. (LAB) had Debt Instrument, Face Amount of $65.58 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFaceAmount · last filed 2023-05-09
- 2023-03-31: Debt Instrument, Face Amount $65.58M.
- 2022-12-31: Debt Instrument, Face Amount $65.58M.
- 2022-09-30: Debt Instrument, Face Amount $65.58M.
- 2022-06-30: Debt Instrument, Face Amount $65.58M.
| Period end | Debt Instrument, Face Amount |
|---|---|
| 2023-03-31 | $65.58M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $65.58M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $65.58M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $65.58M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $90.58M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $72.42M 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |